AngioDynamics, Inc. (NASDAQ:ANGO) Receives Consensus Rating of “Moderate Buy” from Analysts

AngioDynamics, Inc. (NASDAQ:ANGO) has earned an average rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $18.6667.

A number of research firms have recently weighed in on ANGO. Canaccord Genuity Group cut their price target on shares of AngioDynamics from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. Zacks Research lowered shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a report on Monday, March 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a report on Monday, April 20th. Finally, Freedom Capital upgraded shares of AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th.

Institutional Trading of AngioDynamics

Hedge funds have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC raised its holdings in AngioDynamics by 146.4% during the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 1,199 shares during the period. Washington Trust Advisors Inc. acquired a new stake in AngioDynamics during the 3rd quarter worth approximately $27,000. Kemnay Advisory Services Inc. acquired a new stake in shares of AngioDynamics during the fourth quarter worth $27,000. State of Wyoming acquired a new stake in shares of AngioDynamics during the second quarter worth $31,000. Finally, Russell Investments Group Ltd. raised its holdings in shares of AngioDynamics by 329.5% during the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 3,213 shares during the period. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Stock Down 1.6%

Shares of NASDAQ ANGO opened at $12.08 on Friday. AngioDynamics has a 12-month low of $8.36 and a 12-month high of $13.99. The firm’s 50-day simple moving average is $11.09 and its 200 day simple moving average is $11.38. The company has a market cap of $499.15 million, a price-to-earnings ratio of -16.11 and a beta of 0.38.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Thursday, April 2nd. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 4.66% and a negative net margin of 10.01%.The business had revenue of $78.42 million for the quarter, compared to analyst estimates of $76.77 million. On average, equities analysts expect that AngioDynamics will post -0.19 earnings per share for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.